Considering the Experimental Use of Temozolomide in Glioblastoma Research

Temozolomide (TMZ) currently remains the only chemotherapeutic component in the approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour with a dismal patient’s survival prognosis of only ~15 months. While frequently described as an alkylating agent that causes DNA damag...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Biomedicines
Auteurs principaux: Herbener, Verena J., Burster, Timo, Goreth, Alicia, Pruss, Maximilian, von Bandemer, Hélène, Baisch, Tim, Fitzel, Rahel, Siegelin, Markus D., Karpel-Massler, Georg, Debatin, Klaus-Michael, Westhoff, Mike-Andrew, Strobel, Hannah
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7344626/
https://ncbi.nlm.nih.gov/pubmed/32512726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8060151
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires